Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02979899 · ClinicalTrials.gov registry record · Phase 3
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
A Phase 3 study of Advanced Angiosarcoma, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
- 20
- Study locations
NCT02979899: Completed Phase 3 study of Advanced Angiosarcoma, sponsored by Tracon Pharmaceuticals.
NCT02979899 is a Phase 3 study of Advanced Angiosarcoma that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 128 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02979899, a Phase 3 study of Advanced Angiosarcoma, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
Primary Outcome
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Progression free survival is defined as time from randomization to either first disease progression (per independent radiology review of images by RECIST 1.1) or death from any cause.
Conditions Studied
Interventions
- BIOLOGICAL TRC105
- DRUG Votrient
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Northwell Health - Lake Success
- MSKCC - New York
California
- Stanford University - Palo Alto
- Sarcoma Oncology Center - Santa Monica
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Arizona
- University of Arizona Cancer Center - Tucson
Colorado
- University of Colorado Denver - Aurora
Georgia
- Northside Hospital - Sandy Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2019-08-31 |
| Phase | Phase 3 |
What the finished NCT02979899 record still lists
NCT02979899 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Advanced Angiosarcoma appearing as the primary indexed condition, and to 2 interventions - of which TRC105 is the first listed.
NCT02979899 names 20 study sites across 14 states, led by New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02979899 about?
NCT02979899 is a clinical study titled "Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma". This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient)...
What is the current status of trial NCT02979899?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2017-02-13. Estimated completion is 2019-08-31.
What conditions does trial NCT02979899 study?
This clinical trial studies the following conditions: Advanced Angiosarcoma.
What interventions are being tested in trial NCT02979899?
The interventions under investigation include: TRC105 (BIOLOGICAL), Votrient (DRUG).
Who is sponsoring clinical trial NCT02979899?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02979899 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02979899's enrollment target sits among peer trials
128 1601st of 2000 higher than 399 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI